It is important to know exactly at which point the DNA damage signaling is compromised, especially considering that PARP inhibitors are currently used in patients with advanced-stage breast cancer, in the context of germline mutations in BRCA1 or BRCA2 genes, which frequently belong to the triple-negative subtype.62 The gene discussed is PARP1; the disease is breast cancer.